SFM
PCRX icon

Sphera Funds Management’s Pacira BioSciences PCRX Stock Holding History

Sphera Funds Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,000
Closed -$1.61M – 123
2016
Q4 		$1.61M Buy
+50,000
New +$1.67M 0.41% 65

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's PCRX Position: Q1 2017 in Review

Sphera Funds Management sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 50,000 shares — an estimated $1.61M sold.

Sphera Funds Management first reported a position in PCRX in Q4 2016 and held it in 1 quarter. The position peaked at $1.61M in Q4 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

  • Sphera Funds Management reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
  • Sphera Funds Management sold 50,000 Pacira BioSciences shares in Q1 2017, an estimated $1.61M.
  • Sphera Funds Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 1 quarter.
  • Sphera Funds Management's Pacira BioSciences position peaked at $1.61M in Q4 2016.
  • 192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.